Exelixis Inc (NAS:EXEL)
$ 20.91 -0.32 (-1.51%) Market Cap: 6.09 Bil Enterprise Value: 5.33 Bil PE Ratio: 32.52 PB Ratio: 2.90 GF Score: 91/100

Exelixis Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 12, 2020 / 06:20PM GMT
Release Date Price: $26.86 (-2.04%)
Operator

Hello, this webcast presentation is for Bank of America clients only. If you are a member or representative of the press or media, please disconnect now. And now I would like to turn the call over to the moderator. Thank you, and have a good day.

Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

Great. Thank you, and thank you, everybody, for joining us for our next company presentation at Bank of America's Annual Healthcare Conference. My name is Jason Gerberry, and I cover Specialty Pharma and Smid-Cap Biotech at BofA, and I'm pleased to be introducing Exelixis and CEO, Mike Morrissey. Exelixis is focused on oral small molecules for cancer and known for its development of CABOMETYX for both renal and liver cancer. And Mike, thank you so much for joining us today.

Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director

It's great to be here. Wish we were back in Vegas, like the old format, but this is working out great today. So thanks again for inviting us to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot